ORAGENICS INC
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
OGEN$0.34-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. CONSOLIDATED STATEMENTS OF CASH FLOWS
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(20,655,737) | $(14,288,389) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Write off of in process research and development (IPR&D) | 10,273,506 | — |
| Depreciation and amortization | 27,391 | 44,667 |
| Loss (Gain) on sale of fixed assets, net | 29,956 | (10,964) |
| Stock-based compensation expense | 1,016,828 | 742,203 |
| Changes in operating assets and liabilities: | ||
| Other receivables | - | 6,987 |
| Operating Lease Right of Use Assets | 337,629 | - |
| Prepaid expenses and other current assets | 2,000,824 | (1,899,612) |
| Prepaid R&D assets - other assets | - | - |
| Lease Liabilities | (347,075) | |
| Accounts payable and accrued expenses | 25,798 | 176,625 |
| Net cash used in operating activities | (7,290,880) | (15,228,483) |
| Cash flows from investing activities: | ||
| Proceeds from sale of property and equipment | 63,716 | 12,000 |
| Cash paid for IPR&D | (1,000,000) | — |
| Purchase of property and equipment | - | (127,519) |
| Net cash provided by (used in) investing activities | (936,284) | (115,519) |
| Cash flows from financing activities: | ||
| Payments on short-term notes payable | (566,046) | (564,205) |
| Proceeds from issuance of common stock for private placement | 849,926 | 69,289 |
| Borrowings under short term notes payable | — | — |
| Net cash provided by (used in) financing activities | 283,880 | (494,916) |
| Net decrease in cash and cash equivalents | (7,943,284) | (15,838,918) |
| Cash and cash equivalents at beginning of year | 11,426,785 | 27,265,703 |
| Cash and cash equivalents at end of year | $3,483,501 | $11,426,785 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid | $3,347 | $9,290 |
| Non-cash investing and financing activities: | ||
| Borrowings under short term notes payable for prepaid insurance | $611,109 | $528,429 |
| Issuance of Series F Preferred stock for IPR&D | $8,947,834 | $— |
| Value of Series A preferred stock converted into common stock | $— | $415,169 |
| Value of Series B preferred stock converted into common stock | $— | $648,821 |
| Par Value of common stock issued in connection with Series A Preferred Stock Conversion | $— | $7 |
| Par Value of common stock issued in connection with Series B Preferred Stock Conversion | $— | $9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.